These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 21415054)
1. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. Spizzo G; Fong D; Wurm M; Ensinger C; Obrist P; Hofer C; Mazzoleni G; Gastl G; Went P J Clin Pathol; 2011 May; 64(5):415-20. PubMed ID: 21415054 [TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Patriarca C; Macchi RM; Marschner AK; Mellstedt H Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118 [TBL] [Abstract][Full Text] [Related]
4. Frequent EpCam protein expression in human carcinomas. Went PT; Lugli A; Meier S; Bundi M; Mirlacher M; Sauter G; Dirnhofer S Hum Pathol; 2004 Jan; 35(1):122-8. PubMed ID: 14745734 [TBL] [Abstract][Full Text] [Related]
5. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Seligson DB; Pantuck AJ; Liu X; Huang Y; Horvath S; Bui MH; Han KR; Correa AJ; Eeva M; Tze S; Belldegrun AS; Figlin RA Clin Cancer Res; 2004 Apr; 10(8):2659-69. PubMed ID: 15102668 [TBL] [Abstract][Full Text] [Related]
6. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Rao CG; Chianese D; Doyle GV; Miller MC; Russell T; Sanders RA; Terstappen LW Int J Oncol; 2005 Jul; 27(1):49-57. PubMed ID: 15942643 [TBL] [Abstract][Full Text] [Related]
7. EpCAM expression is an indicator of recurrence in basal-like breast cancer. Agboola AJ; Paish EC; Rakha EA; Powe DG; Macmillan RD; Ellis IO; Green AR Breast Cancer Res Treat; 2012 Jun; 133(2):575-82. PubMed ID: 22002520 [TBL] [Abstract][Full Text] [Related]
8. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508 [TBL] [Abstract][Full Text] [Related]
9. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Mohtar MA; Syafruddin SE; Nasir SN; Low TY Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32046162 [TBL] [Abstract][Full Text] [Related]
10. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Cimino A; Halushka M; Illei P; Wu X; Sukumar S; Argani P Breast Cancer Res Treat; 2010 Oct; 123(3):701-8. PubMed ID: 20012351 [TBL] [Abstract][Full Text] [Related]
11. By inhibiting Ras/Raf/ERK and MMP-9, knockdown of EpCAM inhibits breast cancer cell growth and metastasis. Gao J; Liu X; Yang F; Liu T; Yan Q; Yang X Oncotarget; 2015 Sep; 6(29):27187-98. PubMed ID: 26356670 [TBL] [Abstract][Full Text] [Related]
12. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592 [TBL] [Abstract][Full Text] [Related]
13. Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Went P; Dirnhofer S; Salvisberg T; Amin MB; Lim SD; Diener PA; Moch H Am J Surg Pathol; 2005 Jan; 29(1):83-8. PubMed ID: 15613858 [TBL] [Abstract][Full Text] [Related]
14. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. Heine M; Freund B; Nielsen P; Jung C; Reimer R; Hohenberg H; Zangemeister-Wittke U; Wester HJ; Lüers GH; Schumacher U PLoS One; 2012; 7(5):e36258. PubMed ID: 22590529 [TBL] [Abstract][Full Text] [Related]
15. Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas. Fong D; Seeber A; Terracciano L; Kasal A; Mazzoleni G; Lehne F; Gastl G; Spizzo G J Clin Pathol; 2014 May; 67(5):408-14. PubMed ID: 24465008 [TBL] [Abstract][Full Text] [Related]
16. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476 [TBL] [Abstract][Full Text] [Related]
19. EpCAM and its potential role in tumor-initiating cells. Imrich S; Hachmeister M; Gires O Cell Adh Migr; 2012; 6(1):30-8. PubMed ID: 22647938 [TBL] [Abstract][Full Text] [Related]
20. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Fong D; Moser P; Kasal A; Seeber A; Gastl G; Martowicz A; Wurm M; Mian C; Obrist P; Mazzoleni G; Spizzo G Histopathology; 2014 Apr; 64(5):683-92. PubMed ID: 24117877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]